

DUKE UNIVERSITY MEDICAL CENTER

CURRICULUM VITAE

**for
Permanent Record
and the
Appointments and Promotions Committee**

Date Prepared: July 16, 2008

NAME: Judith M. Kramer*, MD, MS

PRIMARY ACADEMIC APPOINTMENT: Associate Professor of Medicine
Division of General Internal Medicine

PRIMARY ACADEMIC DEPARTMENT: Medicine

SECONDARY APPOINTMENT: Associate Professor of Medicine
Division of Clinical Pharmacology
Department of Medicine

PRESENT ACADEMIC RANK AND TITLE: Associate Professor of Medicine

**DATE AND RANK OF FIRST DUKE
FACULTY APPOINTMENT:** 12-1-97
Assistant Clinical Professor

MEDICAL LICENSURE: Medicine: _____ North Carolina 1980-present
Pharmacy: _____ North Carolina 1971-present

SPECIALTY CERTIFICATION AND DATES: American Board of
Internal Medicine - 1980

EDUCATION:	INSTITUTION	DATE	DEGREE
[]

* aka Judith K. LittleJohn

College	University of Wisconsin Madison	1965-1968	None (transferred)
College	University of North Carolina, Chapel Hill	1968-1970	BS-Pharmacy
Graduate or Professional School:	University of North Carolina, Chapel Hill	1970-1972	MS-Pharmacy Master's Thesis (1972): Medication Problems of Emergency Room Users
	University of North Carolina, Chapel Hill	1973-1977	MD

SCHOLARLY SOCIETIES: Alpha Omega Alpha
Rho Chi Society

PROFESSIONAL TRAINING AND ACADEMIC CAREER:

1970-1972	Resident in hospital pharmacy, NC Memorial Hospital, Chapel Hill, NC
1972-1973	Instructor in clinical pharmacy, University of North Carolina School of Pharmacy, Chapel Hill, N.C.
1977-1978	Intern in primary care internal medicine, Massachusetts General Hospital, Boston, MA
1978-1979	Junior resident in primary care internal medicine, Massachusetts General Hospital, Boston, MA
1979-1980	Senior resident in internal medicine, N.C. Memorial Hospital, Chapel Hill, North Carolina
1987-1996	Adjunct Assistant Professor, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill
1996-1997	Private consultant to Duke Clinical Research Institute
1997-1999	Director of Project Leaders, Duke Clinical Research Institute
1997-2006	Assistant Clinical Professor of Medicine, Division of General Internal Medicine, Duke University Medical Center

1997- 2006	Chief Medical Officer, Duke Clinical Research Institute
1999-2002	Co-Principal Investigator, Duke Center for Education and Research on Therapeutics
2000-2001	Professor of Pharmaceutical Sciences, Director of Clinical Research Programs, Campbell University (responsible for developing initial curricula for BS and MS degrees in Clinical Research)
June 2002-Jan 2003	Chairperson, Planning Committee, CERTs Multidisciplinary Risk Management Workshop
2002-2007	Principal Investigator, Duke Center for Education and Research on Therapeutics
May 2003-April 2005	Leader, Faculty/Operations Interface Team, Duke Clinical Research Institute
May 2005-Dec 2005	Chairperson, Cross Therapeutic Area Committee, Duke Clinical Research Institute
May 2005-Sept 2006	Member, Executive Management Committee, Duke Clinical Research Institute
2006-present	Associate Professor, Division of General Internal Medicine, Duke University Medical Center
2006-2008	Regulatory Consultant, Duke Translational Medicine Institute
Jan 2008-present	Executive Director, Clinical Trials Transformation Initiative (CTTI), Duke Translational Medicine Institute

PROFESSIONAL EXPERIENCE – Non Academic

1974	Research assistant, N.C. Area Health Education Program
1980-1985	Private practice of internal medicine, Peachtree Internal Medicine Clinic, P.A., Murphy, N.C. and staff member, Murphy Medical Center
1984-1985	Chief of Staff, Murphy Medical Center
1985-1987	Senior clinical research scientist, Division of Clinical Research, Burroughs Wellcome Co., Research Triangle Park, N.C.

- 1987-1989 Head, Cardiovascular Section, Division of Clinical Research, Burroughs Wellcome Co., Research Triangle Park, N.C.
- 1987-1990 Project Leader, _____, Burroughs Wellcome Co., Research Triangle Park, N.C.
- 1989-1992 Head, Department of Cardiopulmonary Medicine, Division of Clinical Research, Burroughs Wellcome Co., Research Triangle Park, N.C.
- 1992 Wellcome Foundation Ltd.'s Senior Management Forum, International Management Development Programme, London Business School
- 1992 Burroughs Wellcome Management Institute, Kenan Flagler Business School, University of North Carolina, Chapel Hill
- 1992-1993 Executive Director, Division of Clinical Research, Burroughs Wellcome Co., Research Triangle Park, N.C.
- 1993-1994 Vice-President, Division of Clinical Research, Burroughs Wellcome Co., Research Triangle Park, N.C.
- 1994(Jul-Dec) B.W. Co.'s Research & Development Representative for corporate development initiative led by _____ Consulting Group
- 1994-1995 Vice President, Medical; U.S. Director of Clinical Research, Burroughs Wellcome Co., Research Triangle Park, N.C.
- 1995 (Jan-June) Co-chairperson, Process Integration Team, Glaxo-Wellcome, plc
- 1995-1996 International Director, Cardiovascular/Critical Care Clinical Research, Glaxo Wellcome Inc., Research Triangle Park, N.C.

PUBLICATIONS:

1. Refereed Journals:

1. **LittleJohn JK**. Package insert: View of a rural town practitioner. *Drug Information Journal*. 1987;21:63-65.
2. **LittleJohn JK**, Edwards S, Fowler GB, Lucas DO. Adverse experience collection: Perspectives from a biological development program. *Drug Information Journal*. 1991; 25-2:175-180.
3. Kalbfleisch JM, Thadani U, **LittleJohn JK**, Brown G, Magorien R, Kutcher M, Taylor G, Maddox WT, Campbell WB, Perry Jr, J, Spann JF, Vetovec G, Kent R, Armstrong PW. Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction. *Am J Cardiol*. 1992;69:1120-1127.
4. Kase CS, Pessin MS, Zivin JA, DelZoppo GJ, Furlan AJ, Buckley JW, Snipes RG, **LittleJohn JK**. Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. *Am J Med*. 1992;92:384-390.
5. Turi ZG, Goldberg S, **LittleJohn JK**, Vander Ark C, Shadoff N, Karlsberg R, Williams J, Butman S, Stadius ML, Wise K, Buchbinder M, Genton E, Laskey WK, DeMaria A, White C, Sheehan F, Comp PC, Wynne J, Batson-Fowler G, Edwards S, for the Wellcome Tissue Plasminogen Activator Study Group. Dose-related efficacy and bleeding complications of double-chain tissue plasminogen activator in acute myocardial infarction. *Am J Cardiol*. 1993;71:1009-1014.
6. DeWood MA, Kurnik PB, Jolly MK, Abnash CJ, Fareed K, Gorfinkel HJ, Morris DL, Satler L, **LittleJohn JK**. Dose-ranging study with a new two-chain rt-PA in patients with acute myocardial infarction: A multicenter trial. *Clinical Cardiology*. 1993;16:302-310.
7. Kalbfleisch JM, Kurnik PB, Thadani U, DeWood MA, Kent R, Magorien RD, Jain AC, Spaccavento LJ, Morris DL, Taylor GJ, Perry JM, Kutcher MA, Gorfinkel HJ, **LittleJohn JK**. Myocardial infarct artery patency and reocclusion rates after treatment with Duteplase at the dose used in the International Study of Infarct Survival-3. *Am J Cardiol*. 1993;71:386-392.
8. Moser KM, Fedullo PF, **LittleJohn JK**, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. *JAMA*. 1994;271:223-225.

9. Peterson ED, Lansky AJ, **Kramer J**, Anstrom K, Lanzilotta MJ for the National Cardiovascular Network Clinical Investigators. Effect of gender on the outcomes of contemporary percutaneous coronary intervention. *Am J Cardiol.* 2001;88:359-364.
10. Califf RM, DeLong E, Ostbye T, Muhlbaier LH, Chen A, LaPointe NA, Hammill B, McCants CB Jr, **Kramer JM**. Underuse of aspirin in a referral population with documented coronary artery disease. *Am J Cardiol.* 2002;89:653-661.
11. Allen LaPointe NM, **Kramer JM**, DeLong ER, Ostbye T, Hammill BG, Muhlbaier LH, McCants CB Jr, Chen A, Califf RM. Patient-reported frequency of taking aspirin in a population with coronary artery disease. *Am J Cardiol.* 2002;89:1042-1046.
12. LaPointe NM, **Kramer JM**, Weinfurt KP, Califf RM. Practitioner acceptance of the Dofetilide risk-management program. *Pharmacotherapy.* 2002;22(8):1041-1046.
13. Cantor WJ, Miller JM, Hellkamp AS, **Kramer JM**, Peterson ED, Hasselblad V, Zidar JP, Newby LK, Ohman EM. Role of target vessel size and body surface area on outcomes after percutaneous coronary interventions in women. *Am Heart J.* 2002;144:297-302.
14. **Kramer JM**, Bosco LA, Califf RM for the CERTs Steering Committee. "Centers for Education and Research on Therapeutics (CERTs). *Drug Information Journal.* 2002;36:717-723.
15. Shah MR, Hasselblad V, Stinnett SS, **Kramer JM**, Grossman S, Gheorghiadu M, Adams KF Jr, Swedberg K, Califf RM, O'Connor CM. Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure. *Eur J Heart Fail.* 2002;4(3):297-304.
16. Al-Khatib SM, Allen LaPointe NM, Curtis LH, **Kramer JM**, Swann J, Honig P, Califf RM. Outpatient prescribing of antiarrhythmic drugs from 1995 through 2000. *Am J Cardiol.* 2003;91:91-94.
17. Al-Khatib SM, Allen LaPointe NM, **Kramer JM**, Califf RM. What clinicians should know about the QT interval. *JAMA.* 2003;289(16):2120-2127.
18. LaPointe NM, Al-Khatib SM, **Kramer JM**, Califf RM. Knowledge deficits related to the QT interval could affect patient safety. *Ann Noninvasive Electrocardiol.* 2003;8(2):157-160.
19. Kwon HJ, Coté TR, Cuffe MS, **Kramer JM**, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. *Ann Intern Med.* 2003;138:807-811.

20. Allen LaPointe NM, Chen A, Hammill BG, DeLong ER, **Kramer JM**, Califf RM. Evaluation of the Dofetilide risk-management program. *Am Heart J*. 2003;146:894-901.
21. **Kramer JM**, Newby LK, Chang WC, Simes RJ, Van de Werf F, Granger CB, Lee KL, White HD, Piegas LS, Topol EJ, Califf RM, Armstrong PW. International variation in the use of evidence-based medicines for acute coronary syndromes. *Eur Heart J*. 2003;24:2133-2141.
22. LaPointe NM, Pamer C, **Kramer JM**. New antiarrhythmic agents for atrial fibrillation and atrial flutter: U.S. drug market response as an indicator of acceptance. *Pharmacotherapy*. 2003;23(10):1316-1321.
23. Newby LK, Bhapkar MV, White HD, Moliterno DJ, Allen LaPointe NM, Kandzari DE, Verheugt FWA, **Kramer JM**, Armstrong PW, Califf RM for the SYMPHONY and 2nd SYMPHONY Investigators. Aspirin use post-acute coronary syndromes: Intolerance, bleeding and discontinuation. *J Thrombosis and Thrombolysis*. 2003;16(3):119-128.
24. O'Shea JC, **Kramer JM**, Califf RM, Peterson ED. Sharing a commitment to improve cardiovascular devices part I: identifying holes in the safety net. *Am Heart J*. 2004;147:977-984.
25. Peterson ED, Hirshfeld Jr JW, Ferguson B, **Kramer JM**, Califf RM, Kessler LG. Sharing a commitment to improve cardiovascular devices part II: sealing holes in the safety net. *Am Heart J*. 2004;147:985-990.
26. Al-Khatib SM, Allen LaPointe NM, **Kramer JM**, Chen AY, Hammill BG, DeLong L, Califf RM. A survey of health care practitioners' knowledge of the QT interval. *J Gen Intern Med*. 2005;20:392-396.
27. **Kramer JM**. Managing the risks of therapeutic products: proceedings of a workshop. *Pharmacoepidemiol Drug Saf*. 2005; 14:619-628.
28. Newby LK, Allen LaPointe NM, Chen AY, **Kramer JM**, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. *Circulation*. 2006; 113:203-212.
29. Ridley DB, **Kramer JM**, Tilson HH, Grabowski HG, Schulman KA. Spending on postapproval drug safety. *Health Aff*. 2006; 25:429-436.
30. LaPointe NM, DeLong ER, Chen A, Hammill BG, Muhlbaier LH, Califf RM, **Kramer JM**. Multi-faceted intervention to promote beta-blocker use in heart failure. *Am Heart J*. 2006; 151:992-998.

31. Allen LaPointe NM, Curtis LH, Chan A, **Kramer JM**, Elston Lafata J, Gurwitz JH, Raebel MA, Platt R. Frequency of high-risk use of QT-prolonging medications. *Pharmacoepidemiol Drug Saf.* 2006; 15:361-368.
32. **Kramer JM**, Hammill B, Anstrom KJ, Fetterolf D, Snyder R, Charde JP, Hoffman BS, Allen LaPointe N, Peterson E. National evaluation of adherence to beta-blocker therapy for one year after acute myocardial infarction in patients with commercial health insurance. *Am Heart J.* 2006; 152:454-460.
33. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, **Kramer JM**, Harrington RA, Matchar DV, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. *JAMA.* 2007;297:159-168.
34. Curtis JR, Martin C, Saag KG, Patkar N, **Kramer J**, Shatin D, Allison J, Braun MM. Confirmation of Administrative Claims-Identified Opportunistic Infections and Other Serious Potential Adverse Events associated with Tumor Necrosis Factor- α Antagonists and Disease Modifying Anti-rheumatic Drugs. *Arthritis Care Res.* 2007;57(2):343-346.
35. Curtis LH, Hammill BG, Eisenstein EL, **Kramer JM**, Anstrom KJ. Using Inverse Probability-Weighted Estimators in Comparative Effectiveness Analyses With Observational Databases. *Med Care.* 2007;45:S103-S107.
36. Curtis JR, **Kramer JM**, Martin C, Saag KG, Patkar N, Shatin D, Burgess M, Xie A, Braun MM. Heart Failure among Younger Rheumatoid Arthritis and Crohn's Patients Exposed to TNF- α Antagonists. *Rheumatology.* 2007;46:1688-1693.
37. Smith DH, **Kramer JM**, Perrin N, Platt R, Roblin DW, Lane K, Goodman M, Nelson WW, Yang X, Soumerai SB. A randomized trial of direct-to-patient communication to enhance adherence to post-MI beta-blocker therapy. *Arch Intern Med.* 2008;168(5):477-483.
38. Anstrom KJ, Kong DF, Shaw LK, Califf RM, **Kramer JM**, Peterson ED, Rao SV, Matchar DV, Mark DB, Harrington RA, Eisenstein EL. Long-term clinical outcomes following coronary stenting. *Arch Intern Med.* In Press.
39. Rao SV, Califf RM, **Kramer JM**, Peterson ED, Gross TP, Pepine CJ, Williams DO, Donohoe D, Waksman R, Mehran R, Krucoff MW. Postmarket evaluation of breakthrough technologies. *Am Heart J.* In Press.
40. Curtis LH, Greiner MA, Hammill BG, **Kramer JM**, Whellan DJ, Schulman KA, Hernandez AF. Acute and long-term outcomes of heart failure in elderly persons, 2001-2005. *Arch Intern Med.* In Press.

2. **Non-Refereed Publications:** None
3. **Chapters in Books:**

1. Kent RS, **LittleJohn JK**, Batson AG. Thrombolytic efficacy of tissue-type plasminogen activator. *Controversies in Coronary Thrombolysis*, p.3-14,1989.
2. **LittleJohn JK**. The package insert as viewed by the small town private practitioner. *Clinical Drug Trials and Tribulations*, p.275-280, 1988.
4. **Books:** None
5. **Non-authored publications:** None
6. **Other:**
 - a. **Published Scientific Reviews**
None
 - b. **Selected Abstracts**
 1. Bahit MC, Granger CB, Alexander KP, **Kramer J**, Lapointe NMA, Califf RM. Applying the evidence: Opportunity in US for 80,000 additional lives saved per year. *Circulation*. 2000;102:II-873.
 2. Allen LaPointe NM, **Kramer JM**, Hammill BG, Chen A, DeLong ER, Ricketts RK, Muhlbaier LH, McCants Jr CB, Califf RM. Long term adherence to evidence-based therapies for coronary artery disease and heart failure in the outpatient setting. *J Am Coll Cardiol*. 2003;41(suppA):517A.
 3. **Kramer JM**, Fetterolf D, Charde JP, Snyder R, Checkman D, DeLong E, Allen LaPointe N, Hoffman B, Arrington RL, Peterson E. National evaluation of long-term adherence to beta-blocker therapy after acute myocardial infarction in patients with commercial health insurance. *J Am Coll Cardiol*. 2004;43(suppA):415A.
 4. **Kramer JM**, Chen AY, Hammill BG, DeLong ER, Allen LaPointe N, Muhlbaier LH, McCants CB, Califf RM. Time trends and factors associated with outpatient beta-blocker use in patients with heart failure or left ventricular dysfunction. *Circ*. 2004;109(20):e266. Available at: <http://circ.ahajournals.org/cgi/reprint/109/20/e231>. Accessed June 16, 2008.
 5. Curtis JR, Martin C, Saag KG, **Kramer J**, Patkar N, Sharin D, Xie A, Allison JJ, Braun MM. Risk of heart failure among younger adults exposed to Infliximab and Etanercept. *Arthritis Rheum*. 2006; 54(9): S372.
 6. Anstrom K, Curtis L, Massing M, Pelter D, Hernandez A, Dupree C, **Kramer J**. Analyzing comparative effectiveness using inverse

probability-weighted estimators: evidence-based vs. non-evidence-based beta-blockers to treat heart failure. *Pharmacoepidemiol Drug Saf.* 2007; 16(supp 2):S19.

c. Editorials, Position, and Background Papers

1. Califf RM, **Kramer JM**. What have we learned from the calcium channel blocker controversy? *Circ.* 1998;97(16):1529-1531.
2. Califf RM, **Kramer JM**. The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and post-marketing assessment. *Pharmacoepidemiol Drug Saf* In Press.

CONSULTANT APPOINTMENTS

1996-1997	Private Consultant to Duke Clinical Research Institute
2003-present	Consultant to United Mine Workers of America (UMWA) Health and Retirement Funds
2003-2007	Member, External Advisory Committee, University of Alabama at Birmingham Centers for Education and Research on Therapeutics (CERTs)
2004-present	Member, Medical Product Surveillance Network (MedSun) Expert Working Group, Center for Devices and Radiological Health, US Food and Drug Administration
2005-2007	Member, Data Monitoring Committee for _____
2006-present	Member, Drug Safety and Risk Management Advisory Committee, US Food and Drug Administration
April 2008-present	Member, PACE (Pragmatic Approaches to Comparative Effectiveness) Initiative Advisory Board

PROFESSIONAL AWARDS

1976-1977	Educational Scholarship, American Association of University Women
1974	King Edward's Fund Fellow, King Edward's College, London/ University of North Carolina at Chapel Hill
1970	Valedictorian, Undergraduate pharmacy class

ORGANIZATIONS AND PARTICIPATION:

1988-present	American Heart Association
1996-2005 & 2007-present	North Carolina Regulatory Affairs Forum
1999-2007	Centers for Education and Research on Therapeutics (CERTs) Steering Committee
1999-2007	CERTs Public/Private Partnership Committee
2000-present	Reviewer for the American Heart Journal
2003-present	Member, International Society of Pharmacoepidemiology
2005-present	Member, American College of Physicians
2007-present	Reviewer for Circulation
2007-present	Reviewer for JAMA
2007-present	Reviewer for American Journal of Public Health
2007-present	Reviewer for the American Journal of Managed Care

PRESENTATIONS:

1. "Outcomes of Coronary Intervention in Women and the Role of Adjuvant Drug Therapy". Epidemiology of Medical Devices in Women, May 4-5, 1998, Rockville, MD (sponsored by FDA)
2. "Assuring Use of Life-Saving Therapies and Avoiding Misuse of High Risk Therapies" July 10, 2001, Drug Information Association National Meeting
3. "CERTs Project Summaries" July 23, 2001, CERTs Faculty Council Meeting
4. "The 'Centers for Education & Research on Therapeutics'... a National Initiative" July 24, 2001, DCRI Research Conference
5. "Responsibilities of a Principal Investigator in Clinical Research" Duke University Cooperative Cardiovascular Studies group (DUCCS) 1st Annual Research Training Program, October 20, 2001
6. "Underuse of Beta-Blockers for Heart Failure or Left Ventricular Dysfunction in a Community Setting" (poster presentation) January 16, 2002, CERTs Steering Committee Meeting
7. "Changing Practice: Lessons Learned: Promoting beta-blockers for congestive heart failure" January 17, 2002, CERTs Steering Committee Meeting
8. "The Centers for Education and Research on Therapeutics" February 12, 2002, Coalition for Affordable Quality Healthcare (CAQH) Meeting
9. "Measuring the Impact of a Novel Risk Management Program to Improve Patient Safety" March 10, 2002, CERTs Government Day
10. "A Multifaceted Intervention in Outpatient Practices to Promote Beta Blockers for Heart Failure-Early Impressions" March 11, 2002, PATHs Day

11. "International Opportunities for Enhancing the Use of Evidence-Based Medicines for Acute Coronary Syndromes: Insights from the SYMPHONY Studies" (poster presentation) March 18, 2002, American College of Cardiology Meeting
12. "Measuring the Impact of a Novel Risk Management Program to Improve Patient Safety" May 17, 2002, Drug Information Association Meeting
13. "CERTs Synergy- Further Collaboration to elucidate issues on QT prolonging drugs" June 5, 2002, CERTs Steering Committee Meeting
14. "Improving Cardiovascular Drug Therapy: The Duke CERTs Program" October 10, 2002, North Carolina Association of Pharmacists Annual Convention
15. "Improving Cardiovascular Drug Therapy: The Duke Center for Education and Research on Therapeutics" January 24, 2003, UNC Program on Health Outcomes Seminar, Chapel Hill, North Carolina
16. "Assuring Patient Safety and Data Integrity...The Universe of Quality Assurance" February 20, 2003, Duke Clinical Research Training Program Lecture, Duke Clinical Research Institute, Durham, North Carolina
17. "Improving Cardiovascular Drug Therapy: The Duke Center for Education and Research on Therapeutics" March 12, 2003, Pfizer Advanced Clinical Research Program, Durham, NC
18. "Working with an Industry Sponsor" April 10, 2003, Duke Clinical Research Training Program Lecture, Duke Clinical Research Institute, Durham, North Carolina
19. "Regulatory Issues in Clinical Trials: Assuring Patient Safety and Data Integrity" June 11, 2003, Electrophysiology Research Conference, Duke University Medical Center, Durham, North Carolina
20. "Multidisciplinary Perspectives on Managing the Risks of Therapeutic Products" as part of a session entitled "Issues in the Implementation of Risk Management Plans" August 23, 2003, 19th International Conference on Pharmacoepidemiology and 1st International Conference on Therapeutic Risk Management, Philadelphia, Pennsylvania
21. "National Evaluation of Long-Term Adherence to Beta-Blocker Therapy After Acute Myocardial Infarction in Patients With Commercial Health Insurance" March 9, 2004, American College of Cardiology 53rd Annual Scientific Sessions, New Orleans, Louisiana
22. "Beta-blockers in Heart Failure/Left Ventricular Dysfunction: Underuse in the Community – Misaligned Economic Incentives?" (co-presented with Patricia Cowper, PhD) March 30, 2004, Duke Clinical Research Institute Weekly Research Conference, Durham, North Carolina
23. "Working with an Industry Sponsor" April 8, 2004, Duke Clinical Research Training Program Lecture, Duke Clinical Research Institute, Durham, North Carolina

24. "Lessons Learned: Post-market Surveillance of Cardiovascular Devices" Presentation to Institute of Medicine Committee On Post-Market Surveillance of Pediatric Medical Devices, April 15, 2004, Washington, DC
25. "Time trends and factors associated with outpatient beta-blocker use in patients with heart failure or left ventricular dysfunction" Poster presentation at American Heart Association 5th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, May 17, 2004, Washington, DC
26. "National evaluation of adherence to beta-blocker therapy for one year after acute myocardial infarction in patients with commercial health insurance" Poster presentation at American Heart Association 2nd Scientific Conference on Compliance in Healthcare and Research, May 17, 2004, Washington, DC
27. "Working with an Industry Sponsor" April 8, 2005, Duke Clinical Research Training Program Lecture, Duke Clinical Research Institute, Durham, North Carolina
28. "Spending on Post-approval Drug Safety" March 24, 2006, Health Sector Advisory Council, Fuqua School of Business, Duke University, Durham, North Carolina
29. "Pharmacoepidemiology: Context, Needs and Opportunities" March 29, 2006, University of North Carolina at Chapel Hill International Society for Pharmacoepidemiology (UNC ISPE) Student Chapter Meeting, University of North Carolina Medical Center, Chapel Hill, North Carolina
30. "Update on CERTs...How does CERTs relate to what you do?" April 11, 2006, Duke Clinical Research Institute (DCRI) Research Conference, Durham, North Carolina
31. "Post-marketing Drug Safety" November 11, 2006, Clinical Trial Network Best Practices Symposium (satellite conference at American Heart Association Annual Scientific Sessions), Chicago, Illinois
32. "Great Therapies Infrequently Taken: Why Patient Compliance is the Achilles Heel of Therapeutics" March 31, 2007, University of Delaware 18th Annual Update in Cardiology, Newark, Delaware
33. "Maximizing CERTs Efficiency to Support the Science: Issues Raised by the New Centers Preparation Committee" December 11, 2007, CERTs Steering Committee Meeting, Washington, DC
34. "Clinical Trials Transformation Initiative (CTTI): We Need to Reengineer the Clinical Trials System!" March 16, 2008, Society for Clinical Data Management Meeting, Durham, NC
35. "Clinical Trials Transformation Initiative (CTTI): We Need to Reengineer the Clinical Trials System!" April 2, 2008, Pragmatic Randomized Clinical Trials Workshop, Toronto, Ontario, Canada
36. "The World of Pharmacoepidemiology as it Expands" April 28, 2008, International Society for Pharmacoepidemiology (ISPE) Midyear Meeting, Boston, MA